Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations

References

• Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BWG, Compérat E, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013;64:639–53.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77.
   PubMed Web of Science ®Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003;3:CD003231.
   PubMedGoogle Scholar
• Oddens J, Brausi M, Sylvester R, Bono A, Van De Beek C, Van Andel G, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72.
   PubMed Web of Science ®Google Scholar
• Nieder AM, Brausi M, Lamm D, O’Donnell M, Tomita K, Woo H, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005;66:108–25.
   PubMed Web of Science ®Google Scholar
• Lammers RJM, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 2011;60:81–93.
   PubMed Web of Science ®Google Scholar
• Zargar H, Aning J, Ischia J, So A, Black P. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol 2014;11:220–30.
   PubMed Web of Science ®Google Scholar
• Rampersaud EN, Vujaskovic Z, Inman BA. Hyperthermia as a treatment for bladder cancer. Oncol York 2010;24:1149–55.
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–71.
   PubMed Web of Science ®Google Scholar
• Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16:585–9.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo® working party. World J Urol 2009;27:319–24.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol 2003;47:127–39.
   PubMed Web of Science ®Google Scholar
• Sousa A, Inman BA, Piñeiro I, Monserrat V, Pérez A, Aparici V, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia 2014;30:166–70.
   PubMed Web of Science ®Google Scholar
• Soria F, Milla P, Fiorito C, Pisano F, Sogni F, Di Marco M, et al. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I–II study. World J Urol 2015;34:189–195.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cheng K-S, Craciunescu OI, Stauffer PR, Maccarini PF, Arunachalam K, et al. Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma. Med Phys 2012;39:1170–81.
   PubMed Web of Science ®Google Scholar
• Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z. A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer. Int J Hyperthermia 2014;30:171–5.
   PubMed Web of Science ®Google Scholar
• Juang T, Stauffer PR, Craciunescu OA, Maccarini PF, Yuan Y, Das SK, et al. Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer. Int J Hyperthermia 2014;30:176–83.
   PubMed Web of Science ®Google Scholar
• Geijsen ED, de Reijke TM, Koning CC, Zum Vörde Sive Vörding PJ, de la Rosette JJ, Rasch CR, et al. Combining mitomycin C and regional 70 MHz hyperthermia in patients with non-muscle invasive bladder cancer: A pilot study. J Urol 2015;194:1202–8.
   PubMed Web of Science ®Google Scholar
• Uchibayashi T, Yamamoto H, Kunimi K, Koshida K, Ohkawa M, Nakajima K. Radiofrequency capacitive hyperthermia combined with irradiation or chemotherapy for patients with invasive bladder-cancer. Oncol Rep 1995;2:773–5.
   PubMed Web of Science ®Google Scholar
• Kakehi M, Ueda K, Mukojima T, Hiraoka M, Seto O, Akanuma A, et al. Multi-institutional clinical studies on hyperthermia combined with radiotherapy or chemotherapy in advanced cancer of deep-seated organs. Int J Hyperthermia 1990;6:719–40.
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int 2011;107:912–18.
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71; discussion 71–2.
   PubMed Web of Science ®Google Scholar
• Moskovitz B, Halachmi S, Moskovitz M, Nativ O, Nativ O. 10-year single-center experience of combined intravesical chemohyperthermia for nonmuscle invasive bladder cancer. Future Oncol 2012;8:1041–9.
   PubMed Web of Science ®Google Scholar
• Kiss B, Schneider S, Thalmann GN, Roth B. Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer? Int J Urol 2015;22:158–62.
   PubMed Web of Science ®Google Scholar
• Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol Semin Orig Investig 2011;29:259–64.
   PubMed Web of Science ®Google Scholar
• Maffezzini M, Campodonico F, Canepa G, Manuputty EE, Tamagno S, Puntoni M. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol 2014;73:925–30.
   PubMed Web of Science ®Google Scholar
• Volpe A, Racioppi M, Bongiovanni L, D’Agostino D, Totaro A, D’Addessi A, et al. Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy?. Urol Int 2012;89:311–18.
   PubMed Web of Science ®Google Scholar
• Arends TJH, van der Heijden AG, Witjes JA. Combined chemohyperthermia: the 10-years monocentric experience in 160 non-muscle invasive bladder cancer patients. J Urol 2014;192:708–13.
   PubMed Web of Science ®Google Scholar
• Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009;182:1313–7.
   PubMed Web of Science ®Google Scholar
• Ekin RG, Akarken I, Cakmak O, Tarhan H, Celik O, Ilbey YO, et al. Results of intravesical chemo-hyperthermia in high-risk non-muscle invasive bladder cancer. Asian Pacific J Cancer Prev 2015;16:3241–5.
   PubMedGoogle Scholar
• Rietbroek R, Bakker P, Schilthius M, Postma A, Vording P, Gonzalez D, et al. of Weekly loco-regional hyperthermia and cisplatin in patients with previously irradiated recurrent cervical carcinoma or locally advanced bladder cancer. Int J Radiat Oncol Biol Phys 1996;34:887–93.
   PubMed Web of Science ®Google Scholar
• Petrovich Z, Emami B, Kapp D, Sapozink M, Langholz B, Oleson J, et al. Regional hyperthermia in patients with recurrent genitourinary cancer. Am J Clin Oncol 1991;14:472–7.
   PubMed Web of Science ®Google Scholar
• Van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355(9210):1119–25.
   PubMed Web of Science ®Google Scholar
• Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009;93:358–63.
   PubMed Web of Science ®Google Scholar